HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Josep Tabernero

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital and Director of the Vall d’Hebron Institute of Oncology (VHIO). He is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumour-directed targeted therapies and immune therapies.

Based on the idea that each tumor has an independent genetic identity, his research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 400 peer-reviewed papers.

He is currently President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO), and is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO).


Dr Tanios Bekaii-Saab

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, and Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.


Professor Pravin Kaumaya

Dr Kaumaya is Prof of Medicine in the Department of Obstetric Gynecology at Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center.  He is an expert in the fields of vaccine research with an emphasis on peptide vaccines for cancer.

The Kaumaya laboratory investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells.  Novel treatments that combine both prophylactic and immunotherapeutic approaches as well as integrating preclinical and clinical research for the benefits of the cancer patients have been developed. The vaccines target breast, ovarian, lung, pancreatic and colon cancers. Their immune intervention strategies are based on the hypothesis that the design of unique peptides which can recapitulate the exquisite 3-dimensional structure of the tumor antigen and when combined with a “promiscuous” T cell activating species generate vaccine candidates.

Dr Kaumaya has published over 130 peer-reviewed articles in major scientific journals and is a Fellow of the American Association for the Advancement of Science (AAAS).





Professor Ursula Wiedermann

Professor Wiedermann is Professor of Vaccinology and Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna. Currently she also has an appointment as Visiting Professor at the University in Göteborg, Sweden. She has more than 100 peer-reviewed publications and is frequently performing presentations at national and international conferences. Professor Wiedermann was the Principal Investigator for the preclinical development of HER-Vaxx and together with Prof. Zielinski´s Division the Phase I clinical trial of HER-Vaxx in metastatic breast cancer patients was performed. Furthermore she has led the design of the Phase II study for gastric cancer due to commence in 2015.

Professor Wiedermann had studied Medicine in Vienna, Austria. Between 1990-1995 she entered a PhD-program in Sweden at the Institute of Clinical Immunology at the University Gothenburg, focusing her research on mucosal immunity and vaccination. Back in Vienna she continued her research career at the University of Vienna concentrating on mucosal vaccination against allergic diseases. After her habilitation (venia docendi) in 1999 she founded the research group “Mucosal Immunity and Vaccination”. In 2001 she finished her medical training as specialist for “Immunology” and “Specific Prophylaxis and Tropical Hygiene”. At the Institute of Specific Prophylaxis and Tropical Medicine she enlarged her research areas to vaccine development against infectious diseases and tumours, and focused on clinical vaccine trials to study immune responsiveness and immune failures upon vaccination. In 2004 she became Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna and in 2006 she was assigned Professor for Vaccinology at the Medical University Vienna. She is a member of the Supreme Board of Health and the Chairman of the National Committee of Immunization Practice of the Austrian Ministry of Health. Since 2009 she is Speaker of the newly founded Centre for Geographic Medicine at the Medical University Vienna.


Professor Peter Schmid

Prof Schmid is Chair of Cancer Medicine at the prestigious Barts Cancer Institute at Queen Mary University London.  He is also Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He leads the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre.

Prof Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development. 

He has successfully led more than 20 national and international academic clinical studies and is a member of several national and international cancer organizations and research groups.  He has authored or co-authored 165 publications and published a book on the management of bone metastases currently in its third edition. 


Dr Neil Segal

Dr Segal is an oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. His research interests focus on the development of new therapies and more specifically, ways to use the immune system to treat cancer. This parallels the approach taken with Imugene’s HER-Vaxx vaccine, which aims to activate the patient’s immune system to produce its own antibodies. Dr Segal has further clinical expertise in colorectal, pancreatic, bile duct and other gastrointestinal cancers. He holds a Doctorate of Medicine and Philosophy from University of the Witwatersrand in South Africa.


Dr. Yelena Janjigian

Dr. Yelena Janjigian is a medical oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US.  Dr. Janjigian specializes in the treatment of malignancies of the gastrointestinal tract, including esophagus and stomach cancers. Her research focuses on the development of new treatments for patients with esophagus and stomach cancers, and is particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. Dr. Janjigian runs clinical and translational studies designed to develop a better prevention, early diagnosis, staging, and treatment strategies. She is the Principal Investigator on a number of clinical trials at Memorial Sloan Kettering.  Dr. Janjigian received her doctorate in medicne from New York University School of Medicine.   Dr. Janjigian holds board certifications for internal medicine and medical oncology.


© Imugene 2018. All rights reserved. ABN 99 009 179 551